Senaste numret

Privata Affärer
nummer 11

Prenumerera

Läs Online

Senaste numret

Placeringsguiden
nummer 11

Prenumerera

Läs Online

PHOTOCURE ANNOUNCES PAYMENT RECEIVED FOR LUMACAN® DEVELOPMENT

2013-01-02 08:30:29
Oslo, Norway, January 2, 2012: Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, announces today that it has received a payment of US$4.5M from Salix Pharmaceuticals, Inc. (NASDAQ:SLXP) regarding development of Lumacan® to date and the commitment to continue the development.

Lumacan is a photodynamic colorectal diagnostic intended to significantly improve the detection of precancerous and cancerous lesions in the colon through fluorescence diagnosis. Photocure signed a strategic global agreement with Salix for the development and commercialization of Lumacan in October 2010. The collaboration with Salix is progressing well.

Salix is currently developing an optimal oral formulation of Lumacan to be used in clinical studies. During the third quarter of 2012 Salix initiated an exploratory study designed to evaluate fluorescence kinetics of Lumacan following enema administration. The oral prototypes are planned to be introduced into clinical trial in 2013.

Kjetil Hestdal, President and CEO of Photocure, said: "Given its successful expertise and experience in developing and marketing treatments for gastrointestinal diseases, Salix is an excellent partner to take Lumacan to the market. We look forward to continuing the collaboration with Salix on the future development of Lumacan."

For further information, please contact:
 
Photocure
President & CEO Kjetil Hestdal
Tel: + 47 913 19 535, Email: kh@photocure.no

CFO Erik Dahl
Tel: +47 50 55 000, Email: ed@photocure.no

M: Communications
Mary Clark, Amber Bielecka, Hollie Vile
Tel: +44 207920 2361, Email: photocure@mcomgroup.com

Notes to editors
About Lumacan®
Lumacan is being developed to increase the detection rate of polyps and colorectal cancer through fluorescence diagnosis. Colorectal cancer is traditionally diagnosed through colonoscopies (visual examination) with white light. The market for colonoscopies is growing as a result of extensive patient screening programs in Europe and USA. In the US, it is estimated that approximately 14 million colonoscopies are being carried out annually for screening of colorectal cancer. At the same time, it is increasingly being recognized that standard white-light colonoscopy has considerable limitations when it comes to optimal detection of colorectal cancer.

About Photocure ASA
Photocure, headquartered in Oslo Norway, is a specialty pharmaceutical company and world leader in photodynamic technology. Based on our unique proprietary Photocure Technology(TM) platform, Photocure develops and commercializes highly selective and effective solutions within disease areas with high unmet medical need, such as bladder cancer, HPV and precancerous cervical lesions, colorectal cancer and skin conditions. Our aim is to provide solutions which can improve health outcomes for patients worldwide. Photocure is listed on the Oslo Stock Exchange (OSE: PHO). Information about Photocure is available at www.photocure.com.

All trademarks mentioned in this release are protected by law and registered trademarks of Photocure.

This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act).

About Salix Pharmaceuticals, Inc.

Salix Pharmaceuticals, Inc., headquartered in Raleigh, North Carolina, USA develops and markets prescription pharmaceutical products for the prevention and treatment of gastrointestinal diseases. Salix's strategy is to in-license late-stage or marketed proprietary therapeutic drugs, complete any required development and regulatory submission of these products, and market them through the Company's gastroenterology specialty sales and marketing team.

Salix also markets Xifaxan® (rifaximin tablets 200mg and 550mg ), MOVIPREP® (PEG 3350, Sodium Sulfate, Sodium Chloride, Potassium Chloride, Sodium Ascorbate and Ascorbic Acid for Oral Solution), OSMOPREP® (sodium phosphate monobasic monohydrate, USP and sodium phosphate dibasic anhydrous, USP) Tablets,), VISICOL® (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP) Tablets, APRISO(TM) (mesalamine) extended-release capsules 0.375 g., METOZOLV® ODT (metoclopramide HCl), PEPCID® (famotidine) for Oral Suspension, Oral Suspension DIURIL® (Chlorothiazide), AZASAN® Azathioprine Tablets, USP, 75/100 mg, ANUSOL-HC® 2.5% (Hydrocortisone Cream, USP), ANUSOL-HC® 25 mg Suppository (Hydrocortisone Acetate), PROCTOCORT® Cream (Hydrocortisone Cream, USP) 1% and PROCTOCORT® Suppository (Hydrocortisone Acetate Rectal Suppositories) 30 mg. Budesonide foam, crofelemer and rifaximin for additional indications are under development.

For full prescribing information, including BOXED WARNINGS for VISICOL, OSMOPREP and METOZOLV, on Salix products, please visit www.salix.com or contact the Company at 919 862-1000.

Salix trades on the NASDAQ Global Select Market under the ticker symbol "SLXP."

For more information please visit the web site www.salix.com . Information on the web site is not incorporated in Salix' SEC filings.

 

This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)
--
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Photocure ASA via Thomson Reuters ONE

HUG#1667691

Thomson Reuters ONE

Börsguiden

Stockholmsbörsen OMXSPI

fr 17:30 1,51%
9,83% Årsskiftet
 
 
 

222 st

33 st

81 st

Marknadsnoteringar
  • OMXSPI1,51%
  • NASDAQ0,24%
  • EUR -2 öre 9,25 kr
  • Brent +1 80,44 USD
  • DOW JONES0,51%
  • NIKKEI0,33%
  • USD 7 öre 7,46 kr
  • Guld 1 200,80 USD
Vinnare
Fler vinnare
Idag% Senast
Lifco B 32,26 123,00 SEK
Lundin Mining Corporation SDB 8,82 38,73 SEK
Anoto Group 8,23 0,25 SEK
Sensys Traffic 7,69 0,91 SEK
EnQuest PLC 7,55 8,33 SEK
Förlorare
Fler förlorare
Idag% Senast
Medivir B -6,86 105,25 SEK
Nordic Service Partners Holding B -4,40 15,20 SEK
Nordic Mines -3,85 0,03 SEK
Duroc B -3,76 10,25 SEK
NeuroVive Pharmaceutical -3,52 43,90 SEK
Gå direkt till börssidorna

Index

Index % Senast
OMXSPI 1,51 465,30
OMXS30 1,67 1 447,53
OMX Mid Cap 1,02 452,57
OMX Small Cap 0,14 392,03
OMX Nordic SEK PI 1,37 262,64

Utländska index

Index % Senast
Dow Jones Industrial Average 0,51 17 810,06
NASDAQ Composite 0,24 4 712,97
Nikkei 225 0,33 17 357,51
OMX Helsinki_PI 2,32 7 811,67
OMX Copenhagen_PI 0,94 611,74

Valutor

Valuta +/- Kurs Tid
1,00 Euro -0,0012 9,25 kronor 01:35
1,00 Pund 0,0040 11,69 kronor 01:00
100,00 Yen 0,0000 6,34 kronor 01:35
1,00 Dollar 0,0015 7,47 kronor 01:00

Räntor

Ränta +/- Senast Tid
Lång ränta (5 år) -0,01 0,02 16:15
Kort ränta (2 mån) 0,00 0,00 09:30
Senaste aktieanalyserna
Sök
Sök på:
Evenemang
Evenemang
1
dec

Under vår temakväll i Stockholm får du möjlighet att lära dig mer om råvarumarknaden och få experttips om vilka placeringsmöjligheter som är hetast just nu.

Vi söker konkreta placeringsidéer på kort och längre sikt i varor som sprider riskerna i aktiedominerade portföljer.

Placeringsguiden nr 11 ute nu

Årets Fond 2014
Dagens viktigaste händelser

Köp lösnummer här
Prenumerera gratis på nyhetsbrev
Mest lästa artiklarna
1 Hernhag: Därför har vissa "preffar" falnat I veckans aktiechatt diskuterades bland annat om varför vissa preferensakti...
2 Dyrt med uppskov vid bostadsförsäljningar Nollräntan och försämrade möjligheter att skjuta upp beskattningen gör att ...
3 De dyra Sverigefonderna som halkar efter Höga förvaltningsavgifter är långt ifrån en garanti för meravkastning. Fler...
4 Utlandssvenskar bör se över testamenten Nästa år träder EU:s nya arvsrättsförordning i kraft. Det innebär stora fö...
5 Hemfosa ger ut preferensaktier Hemfosa är nästa fastighetsbolag att haka på trenden med preferensaktier. S...
1 Så kan bedragare utnyttja brister i bank-id En majoritet av svenskarna har en elektronisk e-legitimation i form av ban...
2 Dyrt med uppskov vid bostadsförsäljningar Nollräntan och försämrade möjligheter att skjuta upp beskattningen gör att ...
3 Hernhag: Därför har vissa "preffar" falnat I veckans aktiechatt diskuterades bland annat om varför vissa preferensakti...
4 De dyra Sverigefonderna som halkar efter Höga förvaltningsavgifter är långt ifrån en garanti för meravkastning. Fler...
5 Så kan du säkra pensionskapitalet Det kan vara en god idé att minska risken i sitt PPM-sparande när pensioner...

Sparränta med garanti
Lägsta bolåneräntan